Table 1 Model variables reported, tested and shown to change base-case conclusion on cost-effectiveness.

Type of model input	Number of model variables
Variables	Reported	Tested in one-way DSA	Findings available	Changed conclusion
Effectiveness/relative effectiveness of intervention	13	10	7	5
Epidemiological Variables
Assay characteristics	36	34	34	0
Prevalence of high-risk gene variant(s)	11	5	4	2
Prevalence of biomarkers^a	3	0	0	0
Baseline/relative risk in those with high-risk gene variant(s)
Recurrent VTE^b	8	5	5	1
Bleeding^c	3	2	1	1
Baseline/relative risk in those without high-risk gene variant(s)
Recurrent VTE^a	56	25	22	3
Bleeding^c	42	21	14	4
VTE complications^d	12	1	1	0
Other epidemiological variables^e	6	6	4	1
Cost/resource use/unit price
Genetic testing	11	8	7	2
Testing of biomarkers^f	1	0	0	0
Anticoagulation monitoring^g	16	7	4	1
Treatment of VTE	23	12	10	0
Treatment of VTE complications^d	12	0	0	0
Treatment of bleeding	23	11	8	1
Death	1	1	1	0
Utility
Anticoagulation	6	4	3	1
VTE	7	3	2	0
VTE complications^d	6	1	1	0
Bleeding	8	5	3	0
No event/off-treatment	2	2	2	0
Other utility^h	3	1	1	0
Total variables	309	164	134	22

^aPrevalence of lupus anticoagulant, anticardiolipin antibody and antithrombin, protein C or protein S deficiency.
^bVenous thromboembolism and deaths due to venous thromboembolism.
^cHaemorrhage and deaths due to haemorrhage.
^dIncludes non-haemorrhagic stroke and post‐thrombophlebitis syndrome.
^eCompliance to anticoagulation and probability of deaths.
^fTesting for Activated Protein C (in Eckman et al. 2002 [21], a patient must first be shown to be sensitive to Activated Protein C to be eligible for genetic testing).
^gCost of anticoagulation medication and/or monitoring.
^hUtility for short stay in hospitals and utility for death.

Quick links

Search